Biphasic Insulin Aspart
Brand names: NovoMix 30
Biphasic insulin aspart is a premixed insulin combining rapid-acting insulin aspart with a protamine-bound intermediate-acting component, used to manage diabetes mellitus.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The aspart fraction provides rapid postprandial glucose control while the protaminated fraction gives a more prolonged basal effect; insulin lowers glucose by promoting cellular uptake and inhibiting hepatic glucose output.
Prescribing in practice
- Hypoglycaemia is the principal risk, and because it contains a rapid-acting component it should be given with or just before a meal to avoid early hypoglycaemia.
- Insulin requirements change with illness, activity, weight and renal function, so doses need individualised adjustment.
- The pen must be resuspended by gentle mixing before each injection, and brands or insulin preparations should not be switched without clinical supervision.
Monitoring
Monitor blood glucose regularly (including HbA1c) and review injection technique and site rotation to detect hypoglycaemia and lipohypertrophy.
Counselling the patient
- A premixed insulin covering meals and providing background control.
- Resuspend the pen by gentle mixing and inject with or just before meals.
- Know how to recognise and treat low blood sugar and rotate injection sites.
Evidence & guidelines
Premixed biphasic insulin aspart is an established option in diabetes care, with administration timing and hypoglycaemia precautions detailed in NICE guidance and the SPC.
Reference: NICE NG28 (Type 2 DM); MHRA Insulin Safety Alert; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016